Oryzon Genomics S.A. Logo

Oryzon Genomics S.A.

Develops epigenetic-based medicines for cancer and central nervous system disorders.

ORY | MC

Overview

Corporate Details

ISIN(s):
ES0167733015
LEI:
95980063R15RDF29DK13
Country:
Spain
Address:
Sant Ferran 74, 08940 Cornellà de Llobregat
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics. The company leverages its proprietary epigenetic platform to discover, develop, and commercialize innovative, personalized medicines for patients with cancer and central nervous system (CNS) disorders. Its approach focuses on identifying and validating biomarkers and therapeutic targets to create advanced therapies, with a pipeline that includes the development of LSD1 inhibitors for psychiatric and neurodegenerative diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-27 00:00
Post-Annual General Meeting Information
ORYZON anuncia los resultados de la votación de su Junta General Ordinaria de A…
Spanish 44.3 KB
2025-05-26 08:04
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
Spanish 139.0 KB
2025-05-26 00:00
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
Spanish 139.0 KB
2025-05-12 07:52
Earnings Release
La sociedad remite información sobre los resultados del primer trimestre de 2025
Spanish 370.8 KB
2025-05-08 08:06
Regulatory News Service
ORYZON recibe una ayuda no reembolsable de 13,26 millones de € para su proyecto…
Spanish 250.1 KB
2025-04-29 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-04-25 13:52
Declaration of Voting Results & Voting Rights Announcements
Se comunica la inscripción en el Registro mercantil de la escritura de ampliaci…
Spanish 202.4 KB
2025-04-24 08:13
Share Issue/Capital Change
Resultado de la colocación acelerada
Spanish 178.7 KB
2025-04-23 18:34
Share Issue/Capital Change
Lanzamiento de ampliación de capital acelerada
Spanish 195.2 KB
2025-04-23 17:58
Share Issue/Capital Change
Lanzamiento de ampliación de capital acelerada
Spanish 195.2 KB
2025-02-28 14:54
Post-Annual General Meeting Information
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
Spanish 51.6 KB
2025-02-28 00:00
Post-Annual General Meeting Information
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
Spanish 55.0 KB
2025-02-27 19:03
Remuneration Information
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del …
Spanish 189.1 KB
2025-02-27 18:57
Governance Information
La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2024
Spanish 437.0 KB
2025-02-27 00:00
Annual Report
Spanish 13.7 MB

Automate Your Workflow. Get a real-time feed of all Oryzon Genomics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oryzon Genomics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.